A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
Checked against the public recordLast updated Mar 21, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Mayo Clinic
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Stage IB and above non-small cell lung cancer or metastatic lung cancer * Age \>18 years old * Willing and able to consent to study * No prior history of neoadjuvant therapy. Exclusion Criteria: * Age \<18 years old * Unable to provide consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic in RochesterRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 21, 2018. Always confirm current availability with the study team.